RESULTS	At 1-year follow-up , bivalirudin was associated with significantly lower rates of mortality and cardiac mortality compared with unfractionated heparin plus glycoprotein IIb/IIIa inhibitors in patients in the upper WBC tertile ( all-cause death : 4.1 % versus 9.3 % , respectively ; P = 0.0004 ; cardiac death : 2.0 % versus 6.9 % ; respectively ; P < 0.0001 ) but not in patients in the mid-WBC or lower WBC tertiles .\